| Breast cancer is the most common female malignant tumors,which in China accounted for 7% -10%, and showed an upward trend year after year. Breast cancer is the first female malignancy in some major cities .Its etiology and prognosis has been a lot of influence. Surgical treatment of breast cancer tre- atment is one of the main methods, as well as Adjuvant chemotherapy, end- ocrine,Radiotherapy, and biological treatment.Over the past 20 years,a lot of experts believe that breast cancer from the beginning is a systemic disease.therefore, strongly advocated to reduce the scope of Surgery, and enhancement of postoperative adjuvant therapy, cases of hormone receptor- positive are firstly to apply endocrine treatment and receptor negative to apply chemotherapy.Recently trastuzumab injection has been gradually used on the clinic ,which is an effective biological treatment means for patients with HER-2 over-expression to reduce recurrence rate of breast cancer patients who non-response to chemotherapy .Object:In this paper, we retrospectively analysised the correlation between expression of ER ,PR, HER-2 and Patient's prognosis in 1042 breast cancer cases , thus guiding rational clinical treatment, in raising the survival rate of patients with breast cancer it has important significance.Methods:The expression of HER-2,ER and PR was detected by imm- unohisto chemical technique in 1042 cases of breast cancer. Exploring the correlation between expression of HER-2,ER and PR and patient's prognosis.Results:①The positive rate of expression of ER ,PR ,HER-2was 70.6%(736/1042),80.0%(834/1042),18.2%(190/1042)。respectively.②Different ER status in the overall survival curve, 5-year OS of ER-positive was 92.4%, negative group is 79.2% (log-rank testχ2=11.746,p=0.001), there was a significant difference in the OS of different ER status, overall survival of ER-positive group is better than the ER-negative group. Different ER status in disease-free survival curve, 5-year DFS of ER-positive was 81.5%, negative group is 76.7% (log-rank testχ2=4.425,p=0.039), there was a significant difference in the DFS of different ER status,the prognosis of ER positive group is better than ER-negative group.③There was no significant difference in the OS(log-rank testχ2=0.239 ,p=0.625)and DFS (log-rank testχ2=1.149,p=0.274)of the different PR status.④Different HER-2 status in the overall survival curve, 5-year OS of HER-2-positive was 76.4%, negative group is 90.7% (log-rank testχ2=6.918,p=0.009), there was a significant difference in the OS of different HER-2 status, overall survival of HER-2-positive group is worse than the HER-2-negative group. Different HER-2 status in disease-free survival curve, 5-year DFS of HER-2-positive was 70.5%, negative group is 81.8% (log-rank testχ2=2.273,p=0.096), there was no significant difference in the DFS of different HER-2 status.⑤In overall survival , there was no significant difference in combination of different types of receptor(log-rank test,p=0.051), the prognosis of patients with Luminal A is the best, 5-year OS of Luminal A was 91.2%, the prognosis of patients with Basal-like is relatively good, 5-year OS of Basal-like is 86.8%. The prognosis of patients with HER-2-positive and Luminal B is the worst , 5-year OS of HER-2-positive and Luminal B is 72.9% and 77.25%.In disease-free survival, there was no significant difference in combination of different types of recepto(rlog-rank test,p=0.399), the prognosis of patients with Luminal A and Basal-like is the best, 5-year DFS of Luminal A and Basal-like was 81.7% and 81.5%, The prognosis of patients with HER-2-positive and Luminal B is the worst , 5-year OS of HER-2-positive and Luminal B is 69.9% and 70.3%.Conclusion:ER and HER-2 determination is essential to determine the prognosis of breast cancer, but also for clinical development of a comprehensive treatment of breast cancer provides an important basis for the program.
|
PDF Full Text Request